Delgocitinib cream was shown to be effective and well-tolerated in adolescents with chronic hand eczema in the phase 3 DELTA TEEN clinical trial. Dermatology Advisor: Hand Eczema Independently Linked to Quality of Life Burden in Atopic Dermatitis Hand eczema in patients with AD is independently associated with worse QOL measures, with increasing burden seen with increasing hand eczema severity. Hand Eczema Independently Linked to Quality of Life Burden in Atopic Dermatitis Yahoo Finance: LEO Pharma Announces FDA Acceptance of Supplemental NDA for ANZUPGO® (delgocitinib) Cream for the Treatment of Chronic Hand Eczema in Children Aged 12-17 LEO Pharma Announces FDA Acceptance of Supplemental NDA for ANZUPGO® (delgocitinib) Cream for the Treatment of Chronic Hand Eczema in Children Aged 12-17 The American Journal of Managed Care: Chronic Hand Eczema Linked to Multifactorial Triggers, QOL Burden In the phase 2 trial, efficacy was also seen in patients with non-atopic chronic hand eczema treated with the oral JAK inhibitor.

Understanding the Context

Medical News Today: Eczema on fingers and hands: What you need to know Hand eczema is more common in people with a history of atopic eczema and people in frequent contact with water and chemicals. This may include hairdressers, cleaners, chefs, and healthcare ... NEW YORK, NY — For immediate control of a hand eczema flare, the old soak and smear approach with moisturizers or corticosteroids might live on, but they are moving to the back of the shelf for ... Please provide your email address to receive an email when new articles are posted on .

Key Insights

Between 11% and 20% of the population has chronic hand eczema. Respondents used an average of 1.7 prescriptions. A first-in-class topical pan-Janus kinase (JAK) inhibitor significantly improved symptoms of moderate to severe chronic hand eczema in two randomized phase III trials. At week 16, more patients ... Healio: Abrocitinib improved lesions, itch, pain for atopic and non-atopic chronic hand eczema Treatment with abrocitinib, an oral JAK1 inhibitor, led to substantial improvements in the signs and symptoms of chronic hand eczema, including skin lesions and pain, according to new data.

Final Thoughts

Chronic ... Abrocitinib improved lesions, itch, pain for atopic and non-atopic chronic hand eczema